SURPASS-CVOT (tirzepatide): Ongoing trial expected to demonstrate cardiovascular benefits
For practicing pharmacists, it reinforces patient safety through proper guidance
Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 19 Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations Authors Ylmaz N , Bastemir M Received 27 November 2025 Accepted for publication 13 January 2026 Published 30 January 2026 Volume 2026:19 584175 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 4 Editor who approved publication: Dr Halis Akturk Nimet Ylmaz, 1 Mehmet Bastemir 2 1 Department of Gastroenterology, SANKO University Faculty of Medicine, Gaziantep, Turkey
The mean BMI was approximately 36.6 kg/m
It can also reduce stiffness and discomfort by promoting lubrication in the joints
Frequently Asked Questions (FAQs) about Ozempic Weight Loss in Houston (This section will be populated with FAQs based on common patient concerns, drawn from the original data